Your browser is no longer supported. Please, upgrade your browser.
Settings
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E16.48 EPS (ttm)17.41 Insider Own20.00% Shs Outstand106.62M Perf Week-3.37%
Market Cap30.58B Forward P/E11.43 EPS next Y25.09 Insider Trans-0.05% Shs Float79.94M Perf Month-5.46%
Income2.00B PEG2.66 EPS next Q6.33 Inst Own74.40% Short Float2.94% Perf Quarter-8.23%
Sales7.24B P/S4.23 EPS this Y57.40% Inst Trans1.24% Short Ratio3.02 Perf Half Y-31.76%
Book/sh89.34 P/B3.21 EPS next Y7.05% ROA17.00% Target Price389.16 Perf Year-24.55%
Cash/sh25.04 P/C11.46 EPS next 5Y6.21% ROE23.10% 52W Range287.66 - 442.00 Perf YTD-23.20%
Dividend- P/FCF16.04 EPS past 5Y40.30% ROI24.90% 52W High-35.10% Beta1.11
Dividend %- Quick Ratio3.30 Sales past 5Y26.10% Gross Margin93.40% 52W Low-0.28% ATR8.60
Employees7400 Current Ratio3.90 Sales Q/Q20.30% Oper. Margin29.60% RSI (14)39.35 Volatility2.30% 2.95%
OptionableYes Debt/Eq0.07 EPS Q/Q-65.00% Profit Margin28.60% Rel Volume0.98 Prev Close295.02
ShortableYes LT Debt/Eq0.07 EarningsAug 06 BMO Payout0.00% Avg Volume779.33K Price286.85
Recom2.50 SMA20-4.92% SMA50-5.91% SMA200-19.51% Volume765,283 Change-2.77%
Aug-07-19Upgrade Robert W. Baird Neutral → Outperform $410
Jun-18-19Downgrade Argus Buy → Hold
May-23-19Resumed Citigroup Neutral
May-21-19Initiated Credit Suisse Neutral $336
May-08-19Reiterated Canaccord Genuity Hold $408 → $353
Jan-04-19Upgrade Guggenheim Neutral → Buy
Oct-01-18Initiated Cantor Fitzgerald Neutral $415
May-04-18Reiterated Canaccord Genuity Hold $356 → $304
Apr-09-18Downgrade Raymond James Outperform → Mkt Perform
Feb-21-18Downgrade Canaccord Genuity Buy → Hold $522 → $356
Jan-09-18Reiterated Citigroup Neutral $380 → $388
Dec-01-17Downgrade Citigroup Buy → Neutral $480 → $380
Nov-09-17Reiterated RBC Capital Mkts Sector Perform $473 → $425
Oct-24-17Resumed Guggenheim Buy $540
Oct-20-17Downgrade Barclays Equal Weight → Underweight $450 → $395
Sep-29-17Resumed Piper Jaffray Overweight $540
Sep-15-17Initiated RBC Capital Mkts Sector Perform $475
Sep-06-17Resumed Raymond James Outperform $566
Aug-17-17Initiated Evercore ISI Outperform $605
Aug-04-17Reiterated UBS Buy $489 → $535
Aug-22-19 01:26PM  Bill Nygren Drills Into Permian Basin Oil GuruFocus.com
11:55AM  The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron Zacks
Aug-21-19 12:05PM  The Zacks Analyst Blog Highlights: Estee Lauder, Becton, Dickinson, Applied Materials, Regeneron and HollyFrontier Zacks
11:00AM  Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More Zacks
Aug-20-19 05:14PM  Inovio Ends Enrollment in Anal Dysplasia Study on VGX-3100 Zacks
04:46PM  Here's Why AnaptysBio Shares Are Slipping Today Motley Fool
02:28PM  Top Analyst Reports for Estee Lauder, Becton, Dickinson & Applied Materials Zacks
01:06PM  8 Biotech Stocks to Watch After the Q2 Earnings Season InvestorPlace
Aug-15-19 09:30AM  Regeneron Announces Upcoming Investor Conference Presentation PR Newswire
08:28AM  Regeneron Gets FDA Nod for Eylea Injection Prefilled Syringe Zacks
Aug-14-19 12:35PM  Edited Transcript of REGN earnings conference call or presentation 6-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
09:55AM  Is Regeneron Pharmaceuticals (REGN) A Great Pick for Value Investors? Zacks
09:33AM  Regeneron's Drug To Treat Genetic Form Of Bad Cholesterol Aces Late-Stage Trial Benzinga
09:21AM  Biotech Stock Roundup: Amgen's Enbrel Patent Win, AMRN's Setback & More Zacks
08:34AM  Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals Zacks
07:50AM  The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering Benzinga
07:00AM  Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol PR Newswire
Aug-13-19 11:47AM  A Promising Ebola Drug Isnt Helping Regeneron Stock. Heres Why. Barrons.com
11:01AM  Regeneron's Eylea Prefilled Syringe Clears FDA Hurdle Benzinga
10:43AM  Mergers & Acquisitions Take Center Stage in Biotech Industry Zacks
09:50AM  Regeneron Ebola Treatment Shows Promise, Study Stopped Early Zacks
07:00AM  FDA Approves EYLEA® (aflibercept) Injection Prefilled Syringe PR Newswire
Aug-12-19 02:40PM  New experimental Ebola drugs are saving lives in Africa MarketWatch
11:17AM  UPDATE 5-Ebola "no longer incurable" as Congo trial finds drugs boost survival Reuters
10:17AM  Regeneron's Ebola treatment proves superior to rival in trial Reuters
10:14AM  Congo trial of Ebola treatments switches to focus on two drugs Reuters
10:01AM  PALM Ebola Clinical Trial Stopped Early as Regeneron's REGN-EB3 Therapy Shows Superiority to ZMapp in Preventing Ebola Deaths PR Newswire
Aug-10-19 07:56PM  AnaptysBio Prepares for a Potential Gear Shift Motley Fool
Aug-08-19 06:00AM  Regeneron sales grow 20% as it moves ahead with $800 million expansion in East Greenbush American City Business Journals
Aug-07-19 10:03AM  Company News for Aug 7, 2019 Zacks
08:13AM  Alnylam's (ALNY) Q2 Earnings and Revenues Miss Estimates Zacks
Aug-06-19 11:25PM  Regeneron Pharmaceuticals (REGN) Q2 2019 Earnings Call Transcript Motley Fool
04:21PM  This Big Biotech Stock Just Posted An Eye-Popping Earnings Beat Investor's Business Daily
03:00PM  Regeneron Pharmaceuticals Reports Marked Improvement in Q2 Motley Fool
01:09PM  Regeneron (REGN) Q2 Earnings Top Estimates, Eylea Sales Solid Zacks
08:24AM  Regeneron stock up 2.2% after earnings beat MarketWatch
08:18AM  Regeneron Pharmaceuticals Reports Q2 Earnings Beat Benzinga
07:45AM  Regeneron (REGN) Q2 Earnings and Revenues Beat Estimates Zacks
07:06AM  UPDATE 2-Regeneron beats second-quarter profit estimates on Eylea boost Reuters
06:40AM  Regeneron second-quarter revenue beats on Eylea sales Reuters
06:30AM  Regeneron Reports Second Quarter 2019 Financial and Operating Results PR Newswire
02:40AM  Regeneron Pharma Earnings, Revenue Beat in Q2 Investing.com
01:40AM  UPDATE 1-EU approves Sanofi, Regeneron's Dupixent for adolescent eczema cases Reuters
01:15AM  EU regulators approve Sanofi, Regeneron's Dupixent for adolescent cases Reuters
01:04AM  Dupixent® (dupilumab) Showed Positive Topline Results in Phase 3 Trial of Children Aged 6 to 11 Years with Severe Atopic Dermatitis PR Newswire
12:59AM  Dupixent® (dupilumab) Approved by European Commission for Adolescents with Moderate-to-Severe Atopic Dermatitis PR Newswire
Aug-05-19 05:59PM  Sanofi (SNY) Q2 2019 Earnings Call Transcript Motley Fool
05:09PM  Jerome Dodson's Parnassus Endeavor Fund 2nd-Quarter Commentary GuruFocus.com
05:09PM  Jerome Dodson Comments on Regeneron Pharmaceuticals GuruFocus.com
10:59AM  Momenta (MNTA) Q2 Loss Wider Than Expected, Revenues Miss Zacks
10:09AM  Is a Beat in Store for Melinta (MLNT) This Earnings Season? Zacks
09:07AM  Will Cost Control Help Teva (TEVA) Beat on Q2 Earnings? Zacks
08:52AM  Should You Buy Regeneron (REGN) Ahead of Earnings? Zacks
Aug-02-19 11:12AM  bluebird's (BLUE) Loss Wider Than Expected, Revenues Beat Zacks
08:44AM  Is a Beat in the Cards for Regeneron (REGN) Q2 Earnings? Zacks
Aug-01-19 09:21AM  Proteostasis (PTI) to Post Q2 Earnings: What's in Store? Zacks
08:54AM  Is a Beat in Store for Nektar (NKTR) This Earnings Season? Zacks
Jul-31-19 03:23PM  Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt? Simply Wall St.
Jul-30-19 11:53AM  Can GW Pharmaceuticals (GWPH) Deliver a Beat in Q2 Earnings? Zacks
11:31AM  CannTrust (CTST) to Report Q2 Earnings: What's in Store? Zacks
10:38AM  Regeneron (REGN) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Jul-29-19 04:12PM  Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards? Zacks
11:40AM  Axovant (AXGT) to Post Q1 Earnings: What's in the Cards? Zacks
11:08AM  Guardant Health (GH) to Report Q2 Earnings: What's in Store? Zacks
10:38AM  Sanofi (SNY) Q2 Earnings Top, Dupixent Shines, EPS View Up Zacks
Jul-26-19 03:17PM  Exelixis (EXEL) to Report Q2 Earnings: What's in the Cards? Zacks
12:04PM  4 Biotech Stocks Sliding Lower InvestorPlace
11:50AM  Will Strong HIV Sales Drive Gilead's (GILD) Q2 Earnings? Zacks
11:50AM  What's in the Cards for Amarin (AMRN) This Earnings Season? Zacks
11:49AM  Vertex (VRTX) to Post Q2 Earnings: What's in the Cards? Zacks
10:03AM  Will Strong Jakafi Sales Drive Incyte (INCY) Q2 Earnings? Zacks
09:27AM  5 Drug/Biotech Stocks Set to Beat Earnings Estimates in Q2 Zacks
Jul-25-19 11:10AM  Acorda (ACOR) to Post Q2 Earnings: What's in the Cards? Zacks
07:29AM  What's in the Cards for AcelRx (ACRX) This Earnings Season? Zacks
Jul-24-19 09:04AM  Eli Lilly (LLY) to Report Q2 Earnings: What's in Store? Zacks
Jul-23-19 10:56AM  Is a Beat in Store for Repligen (RGEN) This Earnings Season? Zacks
09:29AM  AMAG (AMAG) to Report Q2 Earnings: What's in the Cards? Zacks
Jul-22-19 11:13AM  What's in Store for Anika Therapeutics' (ANIK) Q2 Earnings? Zacks
10:16AM  Alexion (ALXN) to Report Q2 Earnings: What's in the Cards? Zacks
Jul-19-19 09:35AM  Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2? Zacks
Jul-18-19 07:30AM  Regeneron Announces the 2019 Winners of the Regeneron Prize for Creative Innovation PR Newswire
Jul-17-19 11:20AM  Inovio (INO) Ends Some Early-Stage R&D Programs, Cuts Jobs Zacks
Jul-14-19 11:39AM  Stocks That Fell to 3-Year Lows in the Week of July 12 GuruFocus.com
Jul-11-19 12:58PM  4 Medical Stocks to Consider After Federal Judge Blocks Trump Proposal Zacks
11:16AM  FDA Accepts Sanofi's BLA for Myeloma Candidate to Review Zacks
Jul-10-19 05:53PM  US Market Indexes Higher on Wednesday GuruFocus.com
05:07PM  David Herro and Bill Nygren Comment on Regeneron Pharmaceuticals GuruFocus.com
04:57PM  David Herro and Bill Nygren's 2nd Quarter Oakmark Global Select Fund Commentary GuruFocus.com
Jul-09-19 08:15AM  Why Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Looks Like A Quality Company Simply Wall St.
07:55AM  Health care is one of the stock markets healthiest sectors right now MarketWatch
Jul-08-19 09:30AM  Regeneron to Report Second Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on August 6, 2019 PR Newswire
Jul-04-19 10:26AM  Glaxo's Dovato Wins EU Nod, RA Candidate Enters Phase III Zacks
Jul-02-19 04:56PM  Pfizer's Eucrisa Proves Safety in Kids with Atopic Dermatitis Zacks
09:31AM  Regeneron/Sanofi's Libtayo Gets EU Approval for Skin Cancer Zacks
Jul-01-19 11:00AM  Regeneron/Sanofi's Dupixent Gets Positive CHMP Recommendation Zacks
10:00AM  Libtayo® (cemiplimab) Approved for Advanced Cutaneous Squamous Cell Carcinoma in the European Union PR Newswire
Jun-30-19 12:15PM  3 Top Biotech Stocks to Add to Your Watchlist Motley Fool
Jun-29-19 07:44AM  Here are the stock markets winners and losers in the first half of 2019 MarketWatch
Jun-27-19 07:39AM  Regeneron & Sanofi Get FDA Nod for Dupixent Label Expansion Zacks
Jun-26-19 01:46PM  UPDATE 2-FDA approves expanded label for Regeneron/Sanofi's Dupixent Reuters
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi, Bayer, Teva, Mitsubishi Tanabe Pharma, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
VAGELOS P ROYChairman of the BoardMay 24Option Exercise21.25153,7923,268,080468,669May 29 04:16 PM
GOLDSTEIN JOSEPH LDirectorMay 15Sale305.931,000305,93011,323May 15 08:42 PM
STAHL NEILEVP Research and DevelopmentMay 14Sale305.749,8533,012,48322,450May 15 04:02 PM
STAHL NEILEVP Research and DevelopmentMay 13Option Exercise52.0325,0001,300,75047,450May 15 04:02 PM
Fenimore Christopher R.VP ControllerApr 18Option Exercise21.253507,4387,446Apr 18 07:04 PM
SCHLEIFER LEONARD SPresident & CEOMar 21Option Exercise21.251002,125424,062Mar 22 04:03 PM
Fenimore Christopher R.VP ControllerJan 18Option Exercise21.251503,1887,246Jan 18 05:01 PM
GOLDSTEIN JOSEPH LDirectorJan 10Option Exercise273.671,791490,14314,114Jan 11 04:06 PM
GOLDSTEIN JOSEPH LDirectorJan 10Sale410.001,791734,31012,323Jan 11 04:06 PM
Fenimore Christopher R.VP ControllerDec 20Option Exercise21.2567514,3448,944Dec 20 05:36 PM
Fenimore Christopher R.VP ControllerDec 20Sale358.971,848663,3817,096Dec 20 05:36 PM
Fenimore Christopher R.VP ControllerDec 19Option Exercise52.033,450179,5049,871Dec 20 05:36 PM
YANCOPOULOS GEORGEPresident and Chief ScientificDec 13Option Exercise16.80244,0484,100,006167,185Dec 17 04:02 PM
SCHLEIFER LEONARD SPresident & CEODec 13Option Exercise16.80312,5005,250,000488,014Dec 14 04:19 PM
VAGELOS P ROYChairman of the BoardDec 12Sale382.3262,2942,304Dec 14 04:49 PM
GOLDSTEIN JOSEPH LDirectorSep 28Option Exercise273.67709194,03212,709Oct 01 04:06 PM
GOLDSTEIN JOSEPH LDirectorSep 28Sale410.00709290,69012,000Oct 01 04:06 PM
GOLDSTEIN JOSEPH LDirectorSep 27Option Exercise273.672,000547,34014,000Oct 01 04:06 PM
BROWN MICHAEL SDirectorSep 27Option Exercise273.672,000547,3402,000Sep 28 04:35 PM
BROWN MICHAEL SDirectorSep 27Sale392.262,000784,5240Sep 28 04:35 PM
GOLDSTEIN JOSEPH LDirectorSep 27Sale400.002,000800,00012,000Oct 01 04:06 PM
GOLDSTEIN JOSEPH LDirectorSep 24Option Exercise273.672,000547,34013,000Sep 25 04:05 PM
GOLDSTEIN JOSEPH LDirectorSep 24Sale388.652,000777,29012,000Sep 25 04:05 PM
Fenimore Christopher R.VP ControllerAug 30Option Exercise21.25501,063200Aug 31 04:02 PM